Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Transforming growth factor-beta 1 has been shown to suppress the urokinase activity in the glioblastoma cell line T-MG1 and the carcinoma cell line T-CAR1. The molecular mechanisms behind the decrease in the proteolyic activity is shown to be at least partly due to increased synthesis of plasminogen activator inhibitor type-1 and not by decreased synthesis of urokinase.
Helseth
E
E
Institute of Cancer Research, University Hospital of Trondheim, Norway.
Dalen
A
A
Unsgaard
G
G
Skandsen
T
T
Grøndahl-Hansen
J
J
Lund
L R
LR
D015152:Blotting, Northern; D002277:Carcinoma / Q000503:physiopathology*; D005910:Glioma / Q000503:physiopathology*; D006023:Glycoproteins / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D015849:Plasminogen Inactivators; D015291:Transforming Growth Factors / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D006023:Glycoproteins; D015849:Plasminogen Inactivators; D015291:Transforming Growth Factors; D014568:Urokinase-Type Plasminogen Activator